Phase 3 trial of tebentafusp shows promise in metastatic uveal melanoma
Tebentafusp (IMCgp100; IImmunocore) demonstrated superior overall survival (OS) compared to the investigator’s choice in a phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma (mUM), according to a press release.
In the intent-to-treat population, OS Hazard Ratio (HR) favored tebentafusp over investigator’s choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine). The Kaplan-Meier estimates suggest a 1-year OS rate of approximately 73% for tebentafusp versus 58% for investigator’s choice.
“A positive survival benefit for tebentafusp represents a major step towards bringing a potential new treatment for cancer patients with a high unmet need. If approved, tebentafusp would be the first new therapy to improve overall survival in 40 years and to be specifically indicated for metastatic uveal melanoma, a disease with poor survival and where new therapies are urgently needed. We look forward to sharing these data with the medical community and Health Authorities in the near future,” said Bahija Jallal, Chief Executive Officer of Immunocore in a press release.
Read the full press release here.